Condition: Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants · Sponsor: Shanghai JMT-Bio Inc.
This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.
This description comes directly from the study's public registry record.
Clinical Trials Information Group officer · 86-0311-69085587 · ctr-contact@cspc.cn
Zhimin Shao, M.D. · +86 18017312288 · :szm@163.com
Always discuss trial participation with your own doctor first.
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06846437